Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Fulcrum Therapeutics, Inc. Common Stock

FULC

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Last trade $3.72
Day change +$0.01 (+0.27%)
Day range $3.72 – $3.85
Volume 793,952
Market cap $283M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$283.38M
Price / earnings
—
Price / book
0.94×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.22×

Profitability

Earnings per share
-$1.00
Return on assets
-24.56%
Return on equity
-25.28%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
36.19×
Quick ratio
36.19×
Cash ratio
13.56×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$65.24M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for FULC, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$8.44M$7.46M$8.1M$7.28M$7.56M$6.83M$7M$7.72M
Research and development$3.03M$12.44M$14.08M$15.42M$14.3M$12.99M$13.4M$11.71M
Total operating expenses$13.86M$29.31M$22.19M$22.69M$21.86M$19.82M$20.4M$19.43M
Operating income-$13.86M-$29.31M-$22.19M-$22.69M-$21.86M-$19.82M-$20.4M-$19.43M
Interest expense$2.92M$3.13M$0$0$2.26M$2.52M$0$0
Income before taxes-$10.94M-$26.18M-$18.89M-$20.33M-$19.6M-$17.3M-$17.66M-$16.57M
Income taxes$0$0$0$0$0$0$0$0
Net income-$10.94M-$26.18M-$18.89M-$20.33M-$19.6M-$17.3M-$17.66M-$16.57M
Net income attributable to common shareholders-$10.94M-$26.18M-$18.89M-$20.33M-$19.6M-$17.3M-$17.66M-$16.57M
EBITDA-$11.47M-$19.69M-$21.85M-$22.35M-$21.51M-$19.47M-$20.05M-$19.06M
Basic earnings per share-$0.14-$0.34-$0.25-$0.31-$0.31-$0.28-$0.28-$0.27
Diluted earnings per share-$0.14-$0.34-$0.25-$0.31-$0.31-$0.28-$0.28-$0.28

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)

Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Centerspace's acquisition by Independence Realty Trust, Fulcrum Therapeutics' acquisition by Slate Medicines, Weave Communications' acquisition by Francisco Partners, and Personalis' acquisition by Tempus AI.

GlobeNewswire Inc.

Fulcrum Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses

Johnson Fistel is investigating Fulcrum Therapeutics for potential federal securities law violations following the company's June 1, 2026 announcement to discontinue its lead sickle cell drug pociredir due to FDA concerns about PRC2 complex targeting therapies carrying malignancy risks. The disclosure caused a sharp stock price decline, prompting the law firm to investigate potential investor losses and recovery options.

Benzinga

FULC Stock Crashes After Hours: What Investors Need To Know

Fulcrum Therapeutics (NASDAQ: FULC) shares plunged 49.69% in after-hours trading after announcing the discontinuation of pociredir, its lead experimental drug for sickle cell disease, due to FDA concerns about cancer-related risks associated with PRC2 pathway targeting drugs. The company launched a strategic review process to explore merger, acquisition, or other alternatives to maximize shareholder value while preserving its $333.3 million in cash reserves.

GlobeNewswire Inc.

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026

Fulcrum Therapeutics reported positive clinical data for pociredir showing robust fetal hemoglobin induction and improvements in hemolysis markers in sickle cell disease patients. The company plans to initiate a registration-enabling trial in H2 2026 and ended Q1 with $333.3 million in cash, providing runway into 2029. CFO Alan Musso will retire later this year, and Dr. Josh Lehrer joined the board.

GlobeNewswire Inc.

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease

MedicAlert Foundation, the Sickle Cell Disease Association of America (SCDAA), and Fulcrum Therapeutics announced a three-year partnership to improve emergency department care for sickle cell disease patients. The collaboration provides participants with MedicAlert Smart Medical ID Cards linked to secure digital health profiles containing physician-approved pain plans and vital medical information accessible via QR code scanning, aiming to expedite care during acute pain crises.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.